PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma

Immunotherapy targeting programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1) represents promising treatments for human cancers. Our previous studies demonstrated PD-L1 overexpression in some canine cancers, and suggested the therapeutic potential of a canine chimeric anti-PD-L1 monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Maekawa, Naoya, Konnai, Satoru, Nishimura, Maki, Kagawa, Yumiko, Takagi, Satoshi, Hosoya, Kenji, Ohta, Hiroshi, Kim, Sangho, Okagawa, Tomohiro, Izumi, Yusuke, Deguchi, Tatsuya, Kato, Yukinari, Yamamoto, Satoshi, Yamamoto, Keiichi, Toda, Mikihiro, Nakajima, Chie, Suzuki, Yasuhiko, Murata, Shiro, Ohashi, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881100/
https://www.ncbi.nlm.nih.gov/pubmed/33580183
http://dx.doi.org/10.1038/s41698-021-00147-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881100/
https://www.ncbi.nlm.nih.gov/pubmed/33580183
http://dx.doi.org/10.1038/s41698-021-00147-6

Ejemplares similares